Shares of the company were down about 3.9% after the bell. The Arizona-based company posted third-quarter revenue of $977.9 million, down 4.9% sequentially, missing estimates of $987.34 million, ...

Notable insider trades include GOOD JENNIFER L, President & CEO at Trevi Therapeutics Inc (TRVI), who sold 40277 shares on Sep 05 ’24, at $3.11 each, totaling $0.13 million. On May 29 ’24, SCIASCIA ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...

Prospects for a potential merger between health insurers Cigna Group and Humana Inc. hinge on the upcoming US presidential election, analysts said.

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Leerink Partners analysts are forecasting annual sales of $866 million in 2026, compared to a consensus of $362 million. The ...

Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...

In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.